UW Medicine Eye Institute
Welcome,         Profile    Billing    Logout  
 2 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vuletic, Simona
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting
3
70
US
RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control
ReGenTree, LLC
Neurotrophic Keratopathy
07/24
11/24
NCT02025023: Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

Recruiting
3
120
US
5-fluorouracil Injection, 5-FU, Triamcinolone Acetonide, triamcinolone, Incision and Curettage, Triamcinolone Acetonide/5-fluorouracil mixture
University of Washington
Chalazion
07/25
07/26
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
SAFE Study, NCT04907084: Serine and Fenofibrate Study in Patients With MacTel Type 2

Active, not recruiting
2
60
Europe, US
Serine, Fenofibrate
The Lowy Medical Research Institute Limited
Macular Telangiectasia Type 2
03/24
03/24
NCT06140329: Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

Terminated
N/A
1
Europe, US, RoW
PYC Therapeutics
Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy
03/25
03/25
NCT05277870: Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension

Recruiting
N/A
150
US
Nanodropper adaptor, control
University of Washington
Glaucoma, Open-Angle, Ocular Hypertension
06/25
06/25
Sundararajan, Miel
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting
3
70
US
RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control
ReGenTree, LLC
Neurotrophic Keratopathy
07/24
11/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vuletic, Simona
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting
3
70
US
RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control
ReGenTree, LLC
Neurotrophic Keratopathy
07/24
11/24
NCT02025023: Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

Recruiting
3
120
US
5-fluorouracil Injection, 5-FU, Triamcinolone Acetonide, triamcinolone, Incision and Curettage, Triamcinolone Acetonide/5-fluorouracil mixture
University of Washington
Chalazion
07/25
07/26
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
SAFE Study, NCT04907084: Serine and Fenofibrate Study in Patients With MacTel Type 2

Active, not recruiting
2
60
Europe, US
Serine, Fenofibrate
The Lowy Medical Research Institute Limited
Macular Telangiectasia Type 2
03/24
03/24
NCT06140329: Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

Terminated
N/A
1
Europe, US, RoW
PYC Therapeutics
Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy
03/25
03/25
NCT05277870: Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension

Recruiting
N/A
150
US
Nanodropper adaptor, control
University of Washington
Glaucoma, Open-Angle, Ocular Hypertension
06/25
06/25
Sundararajan, Miel
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting
3
70
US
RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control
ReGenTree, LLC
Neurotrophic Keratopathy
07/24
11/24

Download Options